Candidemia and invasive candidiasis are major causes of morbidity and mortality, and their incidence is increasing because of the growing complexity of patients. Five species of Candida (Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis and Candida krusei) account for more than 90% of all diagnosed cases, but their relative frequency varies depending on the population involved, geographical region, previous anti-fungal exposure, and patient age. The best evidence regarding the anti-fungal treatment for invasive candidiasis comes from randomized controlled trials in which more than 85% of the recruited patients had candidemia. In the case of less frequent forms of invasive candidiasis, the recommendations are based on retrospective studies, meta-analyses (when available) and experts’ opinions. A pre-emptive approach based on biomarkers and clinical rules is recommended because of the high rate of infection-related mortality among critically ill patients.

Candidemia and invasive candidiasis in adults : A narrative review / S. Antinori, L. Milazzo, S. Sollima, M. Galli, M. Corbellino. - In: EUROPEAN JOURNAL OF INTERNAL MEDICINE. - ISSN 0953-6205. - 34(2016 Oct), pp. 21-28. [10.1016/j.ejim.2016.06.029]

Candidemia and invasive candidiasis in adults : A narrative review

S. Antinori
Primo
;
M. Galli
Penultimo
;
2016

Abstract

Candidemia and invasive candidiasis are major causes of morbidity and mortality, and their incidence is increasing because of the growing complexity of patients. Five species of Candida (Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis and Candida krusei) account for more than 90% of all diagnosed cases, but their relative frequency varies depending on the population involved, geographical region, previous anti-fungal exposure, and patient age. The best evidence regarding the anti-fungal treatment for invasive candidiasis comes from randomized controlled trials in which more than 85% of the recruited patients had candidemia. In the case of less frequent forms of invasive candidiasis, the recommendations are based on retrospective studies, meta-analyses (when available) and experts’ opinions. A pre-emptive approach based on biomarkers and clinical rules is recommended because of the high rate of infection-related mortality among critically ill patients.
antifungal therapy; candidemia; diagnosis; guidelines; invasive candidiasis; resistance; internal medicine
Settore MED/17 - Malattie Infettive
ott-2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
AntinoriEtAlii_EuropJournInternalMedicine_Candidemia_2016.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 471.93 kB
Formato Adobe PDF
471.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/481042
Citazioni
  • ???jsp.display-item.citation.pmc??? 78
  • Scopus 148
  • ???jsp.display-item.citation.isi??? 138
social impact